LAUREN TIDWELL: Open Payments
NPI 1497204002 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,833 in 166 payments from 22 companies in 2025. Trend: 2023 $1,938 · 2024 $2,126 · 2025 $2,833
Food & beverage: $2,833
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 44 | $513 |
| Novartis Pharmaceuticals Corporation | 19 | $339 |
| UCB, Inc. | 20 | $312 |
| ACADIA Pharmaceuticals Inc | 10 | $199 |
| Janssen Biotech, Inc. | 7 | $191 |
| Merz Pharmaceuticals, LLC | 8 | $181 |
| PFIZER INC. | 12 | $155 |
| ARGENX US, INC. | 6 | $150 |
| Neurocrine BioSciences, Inc. | 6 | $149 |
| Alexion Pharmaceuticals, Inc. | 6 | $116 |
Products named: KESIMPTA, QULIPTA, NUPLAZID, Xeomin, UBRELVY, Briviact, INGREZZA, ULTOMIRIS.
Industry payments across AL — which companies pay providers there.
